Alteogen secures European patent for Keytruda SC, extending protection through 2040
Following the U.S., Alteogen has secured a composition-of-matter patent related to the subcutaneous (SC) formulation of Keytruda in Europe as well. By establishing a foundation for patent protection through 2040, the company is broadening the intellectual property defense network for its Hybrozyme platform across the global market.
Alteogen announced on the..